Crossmark

Rescue Therapy with Intensive Vedolizumab Optimization in a Seventeen-Year-Old Girl with Acute Severe Ulcerative Colitis

Published Online: 2021-01-19

Published Print: 2021-07

Authors

Graziano, Francesco https://orcid.org/0000-0002-4896-1842
Macaluso, Fabio Salvatore

Cassata, Nicola

Citrano, Michele

Orlando, Ambrogio
License Information

Text and Data Mining valid from 2021-01-19

Version of Record valid from 2021-01-19
More Information

Article History

Received: 15 November 2020

Accepted: 6 January 2021

First Online: 19 January 2021

Compliance with Ethical Standards

:

: Ambrogio Orlando served as an advisory board member for AbbVie, MSD, Janssen, Pfizer, Takeda Pharmaceuticals, and received lecture Grants from AbbVie, MSD, Sofar, Chiesi, Janssen, Pfizer, and Takeda Pharmaceuticals. Fabio Salvatore Macaluso served as an advisory board member and/or received lecture Grants from AbbVie, Biogen, MSD, Pfizer, Samsung Bioepis, and Takeda. Other authors: nothing to disclose.

Document is current